Even amid a tech boom, there are deals prompted by declining valuations, revenue shortfalls and delayed product launches. Cooley’s Mehdi Khodadad faced such a situation with Paratek Pharmaceuticals, a Boston company that is developing an antibiotic for people with drug-resistant infections.
Paratek had planned to go public in 2012, but that offering was derailed, in part because of uncertainty surrounding its products. By 2014, the company was further along in the development and regulatory approval process but had an even greater need for cash.
